Translational Research Services
At PGXL, we are continuously looking for avenues to enhance the pharmacogenetic and proteomic disciplines. Our commitment to advancing translational research spans from feasibility and proof-of-principal studies, to post market resolution of discrepant results, or other needed services. We are interested in talking to various inventors for possible support and collaboration in translating their discoveries into clinical practice. To achieve this goal, we are interested in:
- Strategic IP Acquisitions. We are actively seeking various IP’s in the areas of pharmacogenetics or proteomic disciplines with potential application to laboratory medicine and diagnostic testing. We provide rapid CDA or MTA executions to make discussions and collaborations go smoothly.
- Proof-of-Principal Studies. Due to our access to multiple genetic or proteomic technologies, we can rapidly study the feasibility of your invention with regards to implementation as a new test, or as a therapeutic target. Our rapid CDA and MTA services make this phase of study seamless and rapid.
- Clinical Studies. Specific clinical studies either designed by us, or conducted under an established protocol, are routinely conducted at PGXL. We can provide references and testimonies upon request indicating our superior services in conducting clinical studies.
- Post-Market Support Services. Once a product is launched, many issues may arise which require in depth investigation and follow-up. PGXL scientists and staff have performed such activities on many occasions in the past. Please contact us for your specific needs relative to post market support and the services available at PGXL.
- Outcome Studies. PGXL can rapidly put together a protocol and a team to conduct outcome studies relative to specific products and practices. The outcome studies can include: financial impact of incorporating certain testing strategies, overall effects on drug interactions, as well as adverse drug reactions. Please contact us for details.